NCT01471691View on ClinicalTrials.gov

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Branch Retinal Vein OcclusionCentral Retinal Vein OcclusionMacular Edema
Interventions
DRUG

ranibizumab 0.5mg

Standard dose

DRUG

ranibizumab 1.0mg

High dose

Trial Locations (4)

90404

Thomas Hanscom AMC, Santa Monica

90505

South Coast Retina, Torrance

90807

South Coast Retina, Long Beach

92647

South Coast Retina, Huntington Beach

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Hanscom, Thomas, M.D.

INDIV